Brandenburg Kapital - News About Kupando GmbH

Potsdam, March 2026 – The biotech company Kupando has successfully raised an additional €10 million as part of its Series A financing, bringing the total volume of the round to €23 million. The round was again led by Remiges Ventures and co-led by LifeCare Partners. In addition to existing investors, including Brandenburg Kapital, High-Tech Gründerfonds and Ventura Biomed Investors, the Carma Fund joined as a new investor.

Kupando, based in Schönefeld, develops novel immunotherapeutic approaches based on the activation of the innate immune system. Its lead candidate, KUP101, is a dual TLR 4/7 agonist designed for use in both oncology and infectious diseases.

The proceeds will primarily be used to prepare and conduct a Phase 1b clinical study of KUP101 in advanced solid tumors, as well as to advance preclinical programs in infectious diseases.

Brandenburg Kapital has been supporting Kupando since the initial financing round and continues to accompany the company as a long-term investor in the development of its innovative technology platform.

Here you can find the press release: https://www.kupando.com/kupando-secures-additional-e10-million/

About Kupando

KUPANDO is a pioneering biotech company focused on developing innovative therapies to address critical unmet medical needs in cancer and infectious diseases. Its disruptive approach harnesses the power of innate immune stimulation and induction of trained innate immunity by dual Toll-Like Receptor (TLR) agonists. This unique modality underpins the Company’s pipeline of first-in-class, differentiated small molecules with the potential to transform the management of these challenging diseases.

Further information can be found at: www.brandenburg-kapital.de, www.kupando.com